NO20062715L - Skriningsanalyser og fremgangsmater for tumorbehanding - Google Patents
Skriningsanalyser og fremgangsmater for tumorbehandingInfo
- Publication number
- NO20062715L NO20062715L NO20062715A NO20062715A NO20062715L NO 20062715 L NO20062715 L NO 20062715L NO 20062715 A NO20062715 A NO 20062715A NO 20062715 A NO20062715 A NO 20062715A NO 20062715 L NO20062715 L NO 20062715L
- Authority
- NO
- Norway
- Prior art keywords
- soft tissue
- present
- primary tumor
- bone metastasis
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000012216 screening Methods 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 4
- 230000009401 metastasis Effects 0.000 abstract 4
- 238000003556 assay Methods 0.000 abstract 3
- 210000000988 bone and bone Anatomy 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000004872 soft tissue Anatomy 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52039803P | 2003-11-13 | 2003-11-13 | |
US55795104P | 2004-03-31 | 2004-03-31 | |
PCT/US2004/036651 WO2005050200A2 (fr) | 2003-11-13 | 2004-11-04 | Dosages de criblage et procedes de traitement de tumeur |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062715L true NO20062715L (no) | 2006-08-11 |
Family
ID=34623132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062715A NO20062715L (no) | 2003-11-13 | 2006-06-12 | Skriningsanalyser og fremgangsmater for tumorbehanding |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060015952A1 (fr) |
EP (1) | EP1682890A2 (fr) |
JP (1) | JP2007515949A (fr) |
KR (1) | KR20060127409A (fr) |
AR (1) | AR046832A1 (fr) |
AU (1) | AU2004292180A1 (fr) |
BR (1) | BRPI0416305A (fr) |
CA (1) | CA2542215A1 (fr) |
IL (1) | IL174916A0 (fr) |
NO (1) | NO20062715L (fr) |
RU (1) | RU2006120483A (fr) |
TW (1) | TW200526957A (fr) |
WO (1) | WO2005050200A2 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1694322A2 (fr) * | 2003-11-26 | 2006-08-30 | Arqule, Inc. | Methodes de protection contre les radiolesions |
RU2386638C2 (ru) * | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
US7412026B2 (en) * | 2004-07-02 | 2008-08-12 | The Board Of Regents Of The University Of Oklahoma | Phase-contrast x-ray imaging systems and methods |
US20080082367A1 (en) * | 2006-09-29 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
US20080109484A1 (en) * | 2006-09-29 | 2008-05-08 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
US10503872B2 (en) | 2006-09-29 | 2019-12-10 | Gearbox Llc | Computational systems for biomedical data |
US20080082583A1 (en) * | 2006-09-29 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
US10546652B2 (en) * | 2006-09-29 | 2020-01-28 | Gearbox Llc | Computational systems for biomedical data |
US10068303B2 (en) | 2006-09-29 | 2018-09-04 | Gearbox Llc | Computational systems for biomedical data |
US7853626B2 (en) | 2006-09-29 | 2010-12-14 | The Invention Science Fund I, Llc | Computational systems for biomedical data |
US20080082359A1 (en) * | 2006-09-29 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of State Of Delaware | Computational systems for biomedical data |
US20080091730A1 (en) * | 2006-09-29 | 2008-04-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems for biomedical data |
US10095836B2 (en) * | 2006-09-29 | 2018-10-09 | Gearbox Llc | Computational systems for biomedical data |
US8122073B2 (en) | 2006-09-29 | 2012-02-21 | The Invention Science Fund I | Computational systems for biomedical data |
US8491890B2 (en) * | 2008-07-09 | 2013-07-23 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
NZ602824A (en) | 2008-12-05 | 2014-05-30 | Abraxis Bioscience Llc | Sparc binding peptides and uses thereof |
JP2012524818A (ja) | 2009-04-24 | 2012-10-18 | バンダービルト ユニバーシティ | 骨細胞機能および骨成長の抗TGF−βによる誘導法 |
MX2012001244A (es) * | 2009-07-30 | 2012-03-26 | Antisense Pharma Gmbh | Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta. |
WO2011053743A1 (fr) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Dosage immunologique de pcsk9 |
HUE027831T2 (en) * | 2010-03-12 | 2016-11-28 | Genzyme Corp | Combination therapy for breast cancer |
WO2013054320A1 (fr) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam) |
KR101479543B1 (ko) * | 2013-03-15 | 2015-01-07 | 서강대학교산학협력단 | Tfg-tec 융합 컨스트럭트를 이용한 종양 질환의 예방 또는 치료용 물질의 스크리닝 방법 및 이의 용도 |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
MX366359B (es) | 2014-04-27 | 2019-07-05 | Ccam Biotherapeutics Ltd | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). |
CA3008162A1 (fr) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Recepteur d'antigene chimere de type porte ou bispecifique sensible a cd19 et a cd20 |
WO2016100233A1 (fr) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Molécules cytotoxiques réagissant à des ligands intracellulaires pour la destruction sélective médiée par les lymphocytes t |
AU2016331081B2 (en) * | 2015-10-02 | 2021-04-29 | Wake Forest University Health Sciences | Methods and apparatus for modeling cancer metastasis in vitro |
KR20180092947A (ko) * | 2015-10-30 | 2018-08-20 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 형질 전환 성장 인자-베타-반응성 폴리펩티드 및 이의 사용 방법 |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
JP2021534735A (ja) * | 2018-08-21 | 2021-12-16 | アルバート アインシュタイン カレッジ オブ メディスンAlbert Einstein College Of Medicine | ヒトTim−3に対するモノクローナル抗体 |
US20220050996A1 (en) * | 2018-12-15 | 2022-02-17 | The Brigham And Women's Hospital, Inc. | Augmented digital microscopy for lesion analysis |
CN111088227A (zh) * | 2019-12-31 | 2020-05-01 | 广州航华生物医药科技有限公司 | 一种细胞分离培养液和t细胞分离培养的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673341B2 (en) * | 1998-07-06 | 2004-01-06 | Beth Israel Deaconness Medical Center | Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis |
US20010046502A1 (en) * | 2000-02-04 | 2001-11-29 | The Board Of Trustees Of The University Of Illinois | Animal model for testing immunotherapies of spontaneous metastatic disease |
WO2001057061A1 (fr) * | 2000-02-04 | 2001-08-09 | California Pacific Medical Center Research Institute | Nouvelle utilisation de ribozymes afin de bloquer l'expression genetique |
CA2298737A1 (fr) * | 2000-02-10 | 2001-08-10 | Manikkam Suthanthiran | Utilisation de l'antagoniste tgf-.beta. pour inhbiber la formation de cellules cancereuses en progression |
US6632979B2 (en) * | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US6767541B2 (en) * | 2000-03-20 | 2004-07-27 | The Regents Of The University Of California | HER-2/neu overexpression abrogates growth inhibitory pathways |
US20030125251A1 (en) * | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
-
2004
- 2004-11-04 WO PCT/US2004/036651 patent/WO2005050200A2/fr active Application Filing
- 2004-11-04 US US10/981,356 patent/US20060015952A1/en not_active Abandoned
- 2004-11-04 JP JP2006539632A patent/JP2007515949A/ja not_active Withdrawn
- 2004-11-04 KR KR1020067011504A patent/KR20060127409A/ko not_active Application Discontinuation
- 2004-11-04 BR BRPI0416305-2A patent/BRPI0416305A/pt not_active IP Right Cessation
- 2004-11-04 AU AU2004292180A patent/AU2004292180A1/en not_active Abandoned
- 2004-11-04 RU RU2006120483/15A patent/RU2006120483A/ru not_active Application Discontinuation
- 2004-11-04 CA CA002542215A patent/CA2542215A1/fr not_active Abandoned
- 2004-11-04 EP EP04810283A patent/EP1682890A2/fr not_active Withdrawn
- 2004-11-05 AR ARP040104077A patent/AR046832A1/es unknown
- 2004-11-05 TW TW093133935A patent/TW200526957A/zh unknown
-
2006
- 2006-04-10 IL IL174916A patent/IL174916A0/en unknown
- 2006-06-12 NO NO20062715A patent/NO20062715L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20060127409A (ko) | 2006-12-12 |
JP2007515949A (ja) | 2007-06-21 |
TW200526957A (en) | 2005-08-16 |
WO2005050200A2 (fr) | 2005-06-02 |
WO2005050200A9 (fr) | 2005-08-18 |
RU2006120483A (ru) | 2007-12-20 |
BRPI0416305A (pt) | 2007-01-09 |
WO2005050200A3 (fr) | 2005-12-01 |
AU2004292180A2 (en) | 2005-06-02 |
CA2542215A1 (fr) | 2005-06-02 |
AR046832A1 (es) | 2005-12-28 |
IL174916A0 (en) | 2006-08-20 |
AU2004292180A1 (en) | 2005-06-02 |
US20060015952A1 (en) | 2006-01-19 |
EP1682890A2 (fr) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062715L (no) | Skriningsanalyser og fremgangsmater for tumorbehanding | |
ATE296112T1 (de) | Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12 | |
HK1094231A1 (en) | Prebiotic effect analysis | |
EA199700087A1 (ru) | Способ ингибирования катепсина к | |
NO20052955L (no) | Behandling av Huntingtons sykdom med EPA | |
DK0944731T3 (da) | Enzymsensor | |
NO963860L (no) | Isoprenyl-transferase-inhibitorer | |
ATE344029T1 (de) | Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern | |
BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
DE60331229D1 (de) | Verfahren und zusammensetzung zur verbesserung des wachstums von fleischgeflügel | |
ATE392430T1 (de) | Verfahren zur herstellung von dipeptiden | |
CY1108079T1 (el) | Μeθοδος καθαρισμοy μεσοτριoνης | |
NO20055025D0 (no) | Multiplex screening for lysosomale lagringsforstyrrelser (LSD) | |
ATE545658T1 (de) | Verfahren zur behandlung von synovialsarkom | |
DE50310283D1 (de) | Verfahren zur identifizierung von immunreaktiven peptiden | |
BR9915732A (pt) | Geração de anticorpos usando-se vacinação de polinucleotìdeo em espécie de ave | |
DK1611238T3 (da) | Modulatoriske glutamattransportforbindelser og -fremgangsmåder | |
SI2317324T1 (sl) | Postopek identifikacije subjekta, ki mu grozi nevarnost srčne odpovedi z ugotavljanjem nivoja galektina-3 ali trombospondina-2 | |
ATE502050T1 (de) | Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin | |
GB0325817D0 (en) | Method and apparatus for assessing polypeptide aggregation | |
ATE345354T1 (de) | Methode zur identifizierung von helicobacter antigenen | |
ATE298246T1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
BR0104523A (pt) | Métodos e aparelho para selecionar candidatos para entrevista | |
ATE406178T1 (de) | Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen | |
ATE467123T1 (de) | Verfahren zum identifizieren biologisch aktiver mittel und synergistischer kombinationen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |